The Sachs Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. We expect around 200 delegates and there is an online meeting system and meeting facilities to make the event transactional. There will also be two tracks of about 30 presentations by listed and private biotechnology companies seeking licensing/investment.
The Sachs Immuno-Oncology: BD&L and Investment Forum
will feature panels on:
- Pharma-Biotech BD&L
- Immunotherapeutics: ADCs and Combination Therapies
- T Cell Therapeutics
- Academic Medical Center Collaborations
- Investment Roundtable
Confirmed Chairs & Speakers include: (for speakers bios click here)
, Associate Professor, Department of Health Policy and Management,
, Vice President, Immunology Research, Intrexon Corporation
, Chairman, President and CEO, Kite Pharma
, Chief Executive Officer, Curis, Inc.
, Chairman and CEO, Cellectis
, Managing Partner, venBio LLC
, Managing Director and Senior Equity Research Analyst, Jefferies, LLC
, Managing Director, Cowen and Company
, Chief Scientific Officer & V.P. R&D, Argos Therapeutics
, Vice President & Head, Ventures and Early Stage Collaborations,
, President and CEO, Lion Biotechnologies
, CBO, Mersana Therapeutics
, VP, Strategic Industry Ventures, MD Anderson Cancer Center
, SVP, Head of Health Sector, Intrexon Corporation
, Director Business Development Oncology, Global Licensing & Business Development, Merck Serono SA
, President & Chief Executive Officer, AnaptysBio, Inc.
, Director, President & CEO, Sorrento Therapeutics, Inc.
, Senior Medical Director, Internal and External Innovation for Oncology TA, Takeda Pharmaceuticals
, Global Head, Oncology Business Development and Licensing,
Boehringer Ingelheim GmbH
, Senior Director, Strategic Alliances, Broad Institute of MIT and Harvard
, Associate Center Director for Translational Research, Michael McGillicuddy Endowed Chair of Melanoma Research and Treatment, and Director of Cell-based Therapies, Moffitt Cancer Center
, Director, OTMC & Associate General Counsel, Moffitt Cancer Center
, Vice President, Head of Oncology and Cancer Immunology Partnering, Roche
, President & CEO, Del Mar Pharmaceuticals
, Vice President, Business Development and Licensing, Merck Research Laboratories
, Vice President, Worldwide Business Development, Pfizer, Inc.
, VP, Head of Research, Verastem, Inc.
, Director of Research, EcoR1 Capital, LLC
, Founder, Chief Technology Officer, Bellicum Pharmaceuticals, Inc.
, Senior Director, New Venture and Scout, J&J Innovation Center-Boston
, Chief Scientific Officer, The Leukemia and Lymphoma Society
, Director, Ventures & Early Stage Collaborations, AbbVie, Inc.
, Senior Healthcare Analyst, Edison Group
, Executive Director, Business Development, Celgene
, Senior Consultant, Defined Health
, Chief Business Development Officer, Dana-Farber Cancer Institute
, Senior Vice President, Business Development & Strategy,
Bellicum Pharmaceuticals, Inc.
, Vice President, Global Marketing Oncology, Amgen
, Private Equity Partner, OrbiMed Advisors, LLC
Vice President, Head of Partnering & Strategy, Medimmune
, EVP & Chief Scientific Officer, ImmunoGen, Inc.
, Chief Scientific Officer, Executive Vice President, Advaxis, Inc.
, Senior Director, New Product Development, Adaptive Biotechnologies
, Global Head, Business Development and New Products Marketing, Cell & Gene Therapy Unit, Novartis Pharmaceuticals Corporation
, Strategy & Business Development, VP Oncology Corporate Licenses, Sanofi
, Partner, Nextech Invest Ltd
* to be confirmed
Presenting Opportunities for Biotech, Pharmaceutical companies and Patient Advocacy Groups
Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed minute presentations.
Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Chicago forum provides the additional interaction with the academic/scientific and patient advocacy communities.
Sponsorship and Exhibition
Sachs Associates has developed an extensive knowledge
of the key individuals operating within the European and global biotech
industry. This together with a growing reputation for excellence puts
Sachs Associates at the forefront of the industry and provides a powerful
tool by which to increase the position of your company in this market.
Raise your company’s profile directly with
your potential clients. All of our sponsorship packages are tailor made
to each client, allowing your organisation to gain the most out of attending
our industry driven events.
To learn more about
Silvia Kar on +
44 (0)203 463 4890 or
by email: Silvia.
Sponsored and Supported by:
Click the cover below to view/download the online forum guide.
|ONE-TO-ONE PARTNERING SYSTEM
Login in NOW – add your profile directly to the system and start booking your meetings.
|To learn more about
contact Silvia Kar
44 (0)203 463 4890 or
by email: Silvia Kar.
| Meeting Scheduler